Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis

Amir Haddad; Nili Stein; Idit Lavi; Lisa Shynkar; Irina Bergman; Ilan Feldhamer; Arnon Dov Cohen; Walid Saliba; Devy Zisman

doi:10.2147/BTT.S425693

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis

Biologics. 2023 Oct 4:17:129-136. doi: 10.2147/BTT.S425693. eCollection 2023.

Authors

Amir Haddad¹, Nili Stein², Idit Lavi², Lisa Shynkar³, Irina Bergman^{3

4}, Ilan Feldhamer⁵, Arnon Dov Cohen^{5

6}, Walid Saliba^{2

4}, Devy Zisman^{1

4}

Affiliations

¹ Rheumatology Unit, Carmel Medical Center, Haifa, Israel.
² Department of Epidemiology, Clalit Health Services, Haifa, Israel.
³ Internal Medicine Department, Carmel Medical Centre, Haifa, Israel.
⁴ Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
⁵ Chief Physician's Office, Central Headquarters, Clalit Health Services, Tel Aviv, Israel.
⁶ Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel.

Abstract

Introduction: Persistence in drug therapy reflects treatment effectiveness and tolerability. We aim to estimate the persistence of apremilast prescribed to patients with psoriatic arthritis (PsA) and to identify characteristics associated with treatment discontinuation in a real-world setting.

Methods: Patients with PsA treated with apremilast from January 2016 were identified from a large health database and followed until medication stop date (using 3-months grace period), death or the end of observation period (June 2021). Demographic data, Charlson comorbidity index and concomitant and previous use of conventional and biologic DMARDs were extracted. The reasons for drug discontinuation were manually retrieved from patient charts. Time to discontinuation was estimated using survival analysis using Kaplan-Meier functions.

Results: Overall, 568 PsA patients treated with apremilast were identified. The mean age was 55.3±14.0 years, of whom 332 (58.5%) were females, 38.4% were obese (BMI>30), 75.2% had a Charlson comorbidity index>1, 24.1% were on concomitant treatment with methotrexate and 72.4% were biologic naïve. The median persistent period was 6.1,95% CI (5.2-6.9) months in which only 16.9% remained persistent on apremilast. No difference was found with regard to age, sex, socioeconomic status, ethnicity and obesity between patients who were persistent compared to patients who discontinued apremilast. Concomitant treatment with methotrexate and prior history of biologic therapy did not affect drug persistency (log rank P=0.957 and 0.082, respectively). Causes for treatment discontinuation were due to lack of skin efficacy in 19.4%, lack of joint efficacy in 33.3%, combined skin and joint inefficacy at 2.3% and due to side effects in 24.1%.

Conclusion: In this large observational retrospective cohort of patients treated with apremilast, a relatively low drug persistence was observed with 6-month and 1-year survival rates of 50.3% and 31.3%, respectively. Treatment discontinuation was mainly due to joint inefficacy, advocating for more studies for proper patient selection to assure treatment effectiveness and persistency.

Keywords: apremilast; drug persistence; psoriatic arthritis; therapy.

Grants and funding

There is no funding to report.